维普中文期刊产品整合服务
75篇 您的检索式:作者名="Axel W"
    题名 作者 年代 出处 被引量
1Percutaneous left atrial appendage closure:Technical aspects and prevention of periprocedural complications with the watchman device显示文摘Transcatheter closure of the left atrial appendage has been developed as an alternative to chronic oral anticoagulation for stroke prevention in patients with atrial fibrillation, and as a primary therapy for patients with contraindications to chronic oral anticoagulation. The promise of this new intervention compared with warfarin has been supported by several, small studies and two pivotal randomized trial with the Watchman Device. The results regarding risk reduction for stroke have been favourable although acute complications were not infrequent. Procedural complications, which are mainly related to transseptal puncture and device implantation, include air embolism, pericardial effusions/tamponade and device embolization. Knowledge of nature, management and prevention of complications should minimize the risk of complications and allow transcatheter left atrial appendage closure to emerge as a therapeutic option for patients with atrial fibrillation at risk for cardioembolic stroke.Sven M bius-Winkler Nicolas Majunke Marcus Sandri Norman Mangner Axel Linke Gregg W Stone Ingo D hnert Gerhard Schuler Peter B Sick 2015World Journal of Cardiology2015,7,2:14
2Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases显示文摘AIM:To test the occurrence of the Pro12Ala mutation of the peroxisome proliferator-activated receptor-γ (PPARγ)2-gene in patients with non-alcoholic fatty liver disease (NAFLD) or alcoholic fatty liver disease (AFLD).METHODS:DNA from a total of 622 specimens including 259 blood samples of healthy blood donors and 363 histologically categorized liver biopsies of patients with NAFLD (n=263) and AFLD (n=100) were analyzed by Real-time polymerase chain reaction using allele-specific probes.RESULTS:In the NAFLD and the AFLD collective,3% of the patients showed homozygous occurrence of the Ala12 PPARγ2-allele,differing from only 1.5% cases in the healthy population.In NAFLD patients,a high incidence of the Ala12 mutant was not associated with the progression of fatty liver disease.However,we observed a significantly higher risk (odds ratio=2.50,CI:1.05-5.90,P=0.028) in AFLD patients carrying the mutated Ala12 allele to develop inflammatory alterations.The linkage of the malfunctioning Ala12-positive PPARγ2 isoform to an increased risk in patients with AFLD to develop severe steatohepatitis and fibrosis indicates a more prominent anti-inflammatory impact of PPARγ2 in progression of AFLD than of NAFLD.CONCLUSION:In AFLD patients,the Pro12Ala single nuclear polymorphism should be studied more extensively in order to serve as a novel candidate in biomarker screening for improved prognosis.Johannes W Rey Andrea Noetel Aline Hardt Ali Canbay Hakan Alakus Axel zur Hausen Hans Peter Dienes Uta Drebber Margarete Odenthal 2010World Journal of Gastroenterology2010,16,46:11
3Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study显示文摘Axel Bauer Jan W Kantelhardt Petra Barthel Raphael Schneider Timo M?kikallio Kurt Ulm Katerina Hnatkova Albert Sch?mig Heikki Huikuri Armin Bunde Marek Malik Georg Schmidt 2006The Lancet2006,,9523:3
4Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery显示文摘Axel DI Kunert W Goggelmann C 1997Circulation1997,96,2:1
5Cyclodextrin rotaxanes and polyrotaxanes显示文摘Gerhard W Han B H Axel M 2006Chemical Reviews2006,106,:1
6Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery显示文摘Axel DI Kunert W Goggelmann C 1997Circulation1997,96,2:1
7A formula to calculate the standard liver volume in children and its application in pediatric liver transplantation 显示文摘Uta H Friedel W Axel H 2013Transplant Internationa2013,26,12:1
8Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery显示文摘Axel DI Kunert W Goggelmann C 1997Circulation1997,96,:1
9Decleration capacity of heart rate as a prelictor of mortality after myocardial infarction~ cohort study 显示文摘Axel B Jan W K Petra B 2006Lancet2006,367,9523:1
10Operation of a Miniature Redox Hydrogel-Based Pyruvate Sensor in Undiluted Deoxygenated Calf Serum显示文摘Gajovic N Binyamin G Axel W 2000Analytical Chemistry2000,72,13:1
11Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery显示文摘Axel DI Kunert W 1997Circulation1997,1596,2:1
12Combing Lithoclast and ultrasound power in one device for percutaneous nephrolithotomy: In vitro results of a novel and highly effective technology 显示文摘Peter O Jost W Axel H 2003Urology2003,61,1:1
13An equilibrium model of search employment显示文摘ALBRECHT J W AXELL B 1984Journal of Political Economy1984,92,:1
14Paclitaxel in- hibits arterial smooth muscle cell proliferation and migra- tion in vitro and in vivo using local drag delivery 显示文摘Axel D I Kunert W Grogelman C 1997Circulation1997,96,2:1
15The neurally controlled animat:biological brauns acting with simulated bodues 显示文摘 Daniel A Wagenaar Axel W Blau Steve M Potter 2001Autonomous Robots2001,11,:1
16Development of a powder metallurgy process for tungsten components显示文摘VOLKER P BERTHOLD Z PRACHAI N ROBERT R AXEL V W JUERGEN H 2008Fusion Engineering and Design2008,83,1012:1
17An equilibrium model of search employment显示文摘Albrecht J W and B Axell 1984Journal of Political Economy1984,92,:1
18Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery显示文摘 Kunert W Goggelmann C 1997Circulation1997,96,2:1
19Analysis of Recognition of Fructose by Imprinted Polymers显示文摘Rajagopal R Axel W Helmuth M 2008Talanta2008,76,5:1
20Paclitaxel inhibits arterial smoothmusclecel proliferation andmigration in vitroand invivousing local drug delivery显示文摘Axel DI Kunert W Goggelmann C 0,,:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费